MA43159B1 - Dérivés d'indoline-2-one - Google Patents

Dérivés d'indoline-2-one

Info

Publication number
MA43159B1
MA43159B1 MA43159A MA43159A MA43159B1 MA 43159 B1 MA43159 B1 MA 43159B1 MA 43159 A MA43159 A MA 43159A MA 43159 A MA43159 A MA 43159A MA 43159 B1 MA43159 B1 MA 43159B1
Authority
MA
Morocco
Prior art keywords
diseases
disease
disorder
epilepsy
treatment
Prior art date
Application number
MA43159A
Other languages
English (en)
Inventor
Sabine Kolczewski
Theodor Stoll
Jean-Marc Plancher
Delphine Gaufreteau
Remy Halm
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MA43159B1 publication Critical patent/MA43159B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne des dérivés d'indoline-2-one de formule générale (i), les substituants étant définis dans la revendication 1. Les composés peuvent être utilisés dans le traitement de maladies du système nerveux central associées à des symptômes positifs (psychose) et négatifs de la schizophrénie, de l'abus de substances, de la dépendance à l'alcool et aux drogues, de troubles obsessionnels-compulsifs, de troubles cognitifs, de troubles bipolaires, de troubles de l'humeur, de la dépression majeure, de la dépression résistante au traitement, de troubles de l'anxiété, de la maladie d'alzheimer, de l'autisme, de la maladie de parkinson, de douleurs chroniques, de troubles de la personnalité limite, de maladies neurodégénératives, de troubles du sommeil, du syndrome de fatigue chronique, de la crispation, de maladies inflammatoires, de l'asthme, de la chorée de huntington, du tdah, de la sclérose latérale amyotrophique, des effets de l'arthrite, de maladies auto-immunes, d'infections virales et fongiques, de maladies cardio-vasculaires, de maladies ophtalmologiques et de maladies inflammatoires de la rétine, de problèmes d'équilibre, de l'épilepsie et de troubles neurodéveloppementaux avec épilépsie comorbide.
MA43159A 2015-11-06 2016-11-02 Dérivés d'indoline-2-one MA43159B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15193342 2015-11-06
PCT/EP2016/076332 WO2017076852A1 (fr) 2015-11-06 2016-11-02 Dérivés d'indoline-2-one

Publications (1)

Publication Number Publication Date
MA43159B1 true MA43159B1 (fr) 2020-08-31

Family

ID=54476820

Family Applications (1)

Application Number Title Priority Date Filing Date
MA43159A MA43159B1 (fr) 2015-11-06 2016-11-02 Dérivés d'indoline-2-one

Country Status (34)

Country Link
US (2) US10710985B2 (fr)
EP (1) EP3371168B1 (fr)
JP (1) JP6857662B2 (fr)
KR (1) KR20180080305A (fr)
CN (1) CN108349944B (fr)
AR (1) AR106588A1 (fr)
AU (1) AU2016348493B2 (fr)
BR (1) BR112018008056A2 (fr)
CA (1) CA3002489C (fr)
CL (1) CL2018001085A1 (fr)
CO (1) CO2018005718A2 (fr)
CR (1) CR20180255A (fr)
DK (1) DK3371168T3 (fr)
ES (1) ES2808920T3 (fr)
HK (1) HK1257170A1 (fr)
HR (1) HRP20201158T1 (fr)
HU (1) HUE050083T2 (fr)
IL (1) IL258656A (fr)
LT (1) LT3371168T (fr)
MA (1) MA43159B1 (fr)
MX (1) MX2018005121A (fr)
MY (1) MY197370A (fr)
PE (1) PE20181885A1 (fr)
PH (1) PH12018500978A1 (fr)
PL (1) PL3371168T3 (fr)
PT (1) PT3371168T (fr)
RS (1) RS60504B1 (fr)
RU (1) RU2727179C2 (fr)
SG (1) SG11201803796SA (fr)
SI (1) SI3371168T1 (fr)
TW (1) TWI631117B (fr)
UA (1) UA122589C2 (fr)
WO (1) WO2017076852A1 (fr)
ZA (1) ZA201802411B (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017076932A1 (fr) 2015-11-06 2017-05-11 F. Hoffmann-La Roche Ag Dérivés d'indoline-2-one utiles dans le traitement de maladies du système nerveux central
CN108137561B (zh) 2015-11-06 2021-03-26 豪夫迈·罗氏有限公司 二氢吲哚-2-酮衍生物
EP3371169B1 (fr) 2015-11-06 2019-07-17 H. Hoffnabb-La Roche Ag Dérivés indolin-2-one destinés à être utilisés dans le traitement du snc et de troubles apparentés
CN108349944B (zh) 2015-11-06 2021-03-30 豪夫迈·罗氏有限公司 二氢吲哚-2-酮衍生物
WO2021067626A2 (fr) 2019-10-01 2021-04-08 Intima Bioscience, Inc. Génie génétique de champignons pour moduler l'expression de tryptamine
EP4143158A1 (fr) * 2020-04-29 2023-03-08 Basf Se Préparation de carboxyamides aromatiques par réaction de carbonylation catalysée au palladium

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3932953A1 (de) * 1989-10-03 1991-04-11 Boehringer Mannheim Gmbh Neue 2-bicyclo-benzimidazole, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
DE3935514A1 (de) 1989-10-25 1991-05-02 Boehringer Mannheim Gmbh Neue bicyclo-imidazole, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
TW251284B (fr) 1992-11-02 1995-07-11 Pfizer
DE4427648A1 (de) 1994-08-04 1996-02-08 Basf Ag N-Stubstituierte 3-Azabicyclo[3,2,0,]heptan-Derivate, ihre Herstellung und Verwendung
FR2757157B1 (fr) 1996-12-13 1999-12-31 Sanofi Sa Derives d'indolin-2-one, procede pour leur preparation et compositions pharmaceutiques les contenant
EP0999840B1 (fr) 1997-06-16 2003-05-02 Janssen Pharmaceutica N.V. Utilisation d' un analogue de draflazine dans le traitement de la douleur
AU2494300A (en) 1999-01-07 2000-07-24 American Home Products Corporation 3,4-dihydro-2h-benzo(1,4)oxazine derivatives
IT1318403B1 (it) 2000-03-17 2003-08-25 Cooperativa Ct Ricerche Poly T Esteri polisaccaridici di n-derivati di acido glutammico.
AU2001249397A1 (en) 2000-03-24 2001-10-08 Cor Therapeutics, Inc. Oxindole inhibitors of factor xa
FR2807038B1 (fr) * 2000-04-03 2002-08-16 Sanofi Synthelabo Nouveaux derives d'indolin-2-one, leur preparation et les compositions pharmaceutiques les contenant
EP1634594A1 (fr) 2000-06-29 2006-03-15 NeuroSearch A/S Utilisation de derives d'oxindole 3-substitue comme modulateurs du canal potassique KCNQ
US6524302B2 (en) 2001-04-26 2003-02-25 Scimed Life Systems, Inc. Multi-lumen catheter
AU2003300124A1 (en) 2002-12-31 2004-07-29 BUOLAMWINI, John, K Novel nucleoside transport inhibitors
RS20060619A (sr) 2004-05-11 2008-06-05 Egis Gyogyszergyar Nyrt., Piridinski derivati alkil oksindola kao aktivna sredstva koja deluju na 5-ht7 receptor
ES2294400T3 (es) 2004-06-29 2008-04-01 Grunenthal Gmbh Nuevos analogos de notrobenciltioinosina.
US20060253263A1 (en) 2005-04-11 2006-11-09 Meshkin Brian J Method to optimize drug selection, dosing and evaluation and to help predict therapeutic response and toxicity from immunosuppressant therapy
AR053713A1 (es) 2005-04-20 2007-05-16 Xenon Pharmaceuticals Inc Compuestos heterociclicos y sus usos como agentes terapeuticos
AR056317A1 (es) 2005-04-20 2007-10-03 Xenon Pharmaceuticals Inc Compuestos de oxindol y composicion farmaceutica
JP2009501184A (ja) 2005-07-13 2009-01-15 エフ．ホフマン−ラ ロシュ アーゲー ５−ｈｔ６、５−ｈｔ２４としてのベンゾイミダゾール誘導体
MX2008010671A (es) * 2006-02-21 2008-10-01 Amgen Inc Derivados de cinolina como inhibidores de fosfodiesterasa 10.
WO2007103373A2 (fr) 2006-03-07 2007-09-13 Combinatorx, Incorporated Compositions et procédés pour le traitement de troubles immunoinflammatoires
EP2032135A2 (fr) * 2006-06-26 2009-03-11 Helicon Therapeutics, Inc. Procédé permettant de moduler la croissance de neurites à l'aide d'un antagoniste du récepteur de la galanine de type 3
US7952109B2 (en) 2006-07-10 2011-05-31 Alcatel-Lucent Usa Inc. Light-emitting crystal structures
WO2008046083A2 (fr) 2006-10-12 2008-04-17 Xenon Pharmaceuticals Inc. Utilisation de composés oxindole comme agents thérapeutiques
PE20081401A1 (es) * 2006-12-28 2008-10-24 Hoffmann La Roche Derivados de indol como antagonistas de receptores vasopresina
WO2008080970A1 (fr) 2006-12-30 2008-07-10 Abbott Gmbh & Co. Kg Dérivé d'oxindole substitué et son utilisation comme ligand du récepteur de la vasopressine
UY30846A1 (es) 2006-12-30 2008-07-31 Abbott Gmbh & Amp Derivados de oxindol sustituidos, medicamentos que los comprenden y uso de los mismos
WO2009018275A1 (fr) 2007-07-30 2009-02-05 University Of Rochester Adénosine et ses substances mimétiques, modulateurs, inhibiteurs de transport et agonistes de récepteur en tant qu'outil thérapeutique pour remplacer ou améliorer l'efficacité d'une stimulation du cerveau profond
JO3126B1 (ar) 2007-11-14 2017-09-20 Janssen Pharmaceutica Nv مثبطات ناقل نيوكليوسيد متوازن اي ان تي 1
EP2219666A4 (fr) 2007-11-15 2011-05-25 Univ North Carolina Phosphatase acide prostatique pour le traitement de la douleur
EP2108641A1 (fr) * 2008-04-11 2009-10-14 Laboratorios Almirall, S.A. Nouveaux dérivés substitués de spiro[cycloalkyl-1,3'-indo]-2'(1'H)-one et leur utilisation comme ihibiteurs de p38 mitogen-activated kinase
EP2113503A1 (fr) * 2008-04-28 2009-11-04 Laboratorios Almirall, S.A. Nouveaux dérivés d'indolin-2-one substitués et leur utilisation comme inhibiteurs de p38 mitogen-activated kinase
JO3265B1 (ar) 2008-12-09 2018-09-16 Novartis Ag مثبطات بيريديلوكسى اندولات vegf-r2 واستخدامها لعلاج المرض
WO2012143510A1 (fr) * 2011-04-21 2012-10-26 Bayer Intellectual Property Gmbh Pyrazolopyridines substituées par un fluoro-alkyle et leur utilisation
ES2621257T3 (es) * 2012-04-20 2017-07-03 Annji Pharmaceutical Co., Ltd. Ésteres de ciclopropanocarboxilato de análogos de purinas
AU2013314417B2 (en) * 2012-09-13 2016-01-21 F. Hoffmann-La Roche Ag 2-oxo-2,3-dihydro-indoles for the treatment of CNS disorders
RU2666532C2 (ru) 2013-06-19 2018-09-11 Ф. Хоффманн-Ля Рош Аг Производные индолин-2-она или пирролопиридин/пиримидин-2-она
CR20160578A (es) 2014-06-26 2017-02-21 Hoffmann La Roche Derivados de indolin-2-ona o pirrolo-piridin-2-ona
MA41841A (fr) 2015-03-30 2018-02-06 Global Blood Therapeutics Inc Composés aldéhyde pour le traitement de la fibrose pulmonaire, de l'hypoxie, et de maladies auto-immunes et des tissus conjonctifs
US10899757B2 (en) 2015-11-06 2021-01-26 Samumed, Llc 2-(1H-indazol-3-yl)-3H-imidazo[4,5-C]pyridines and their anti-inflammatory uses thereof
CN108349944B (zh) 2015-11-06 2021-03-30 豪夫迈·罗氏有限公司 二氢吲哚-2-酮衍生物
ES2915266T3 (es) 2015-11-06 2022-06-21 Neurocrine Biosciences Inc Derivados de N-[2-(1-bencilpiperidin-4-il)etil]-4-(pirazin-2-il)-piperazin-1-carboxamida y compuestos relacionados como antagonistas del receptor muscarínico 4 (M4) para el tratamiento de enfermedades neurológicas
EP3371169B1 (fr) 2015-11-06 2019-07-17 H. Hoffnabb-La Roche Ag Dérivés indolin-2-one destinés à être utilisés dans le traitement du snc et de troubles apparentés
CN108137561B (zh) 2015-11-06 2021-03-26 豪夫迈·罗氏有限公司 二氢吲哚-2-酮衍生物
WO2017076932A1 (fr) 2015-11-06 2017-05-11 F. Hoffmann-La Roche Ag Dérivés d'indoline-2-one utiles dans le traitement de maladies du système nerveux central

Also Published As

Publication number Publication date
CA3002489A1 (fr) 2017-05-11
US20200299278A1 (en) 2020-09-24
EP3371168B1 (fr) 2020-05-27
JP6857662B2 (ja) 2021-04-14
SI3371168T1 (sl) 2020-08-31
CL2018001085A1 (es) 2018-08-24
BR112018008056A2 (pt) 2018-10-23
RU2018120703A3 (fr) 2020-01-31
HUE050083T2 (hu) 2020-11-30
US20180251449A1 (en) 2018-09-06
DK3371168T3 (da) 2020-08-03
AU2016348493A1 (en) 2018-04-26
RU2018120703A (ru) 2019-12-06
EP3371168A1 (fr) 2018-09-12
CO2018005718A2 (es) 2018-06-12
HK1257170A1 (zh) 2019-10-18
CN108349944A (zh) 2018-07-31
PH12018500978A1 (en) 2019-01-28
CA3002489C (fr) 2023-11-07
US11066393B2 (en) 2021-07-20
KR20180080305A (ko) 2018-07-11
ES2808920T3 (es) 2021-03-02
CR20180255A (es) 2018-06-22
TWI631117B (zh) 2018-08-01
PT3371168T (pt) 2020-07-17
WO2017076852A1 (fr) 2017-05-11
ZA201802411B (en) 2019-01-30
RS60504B1 (sr) 2020-08-31
HRP20201158T1 (hr) 2020-11-13
UA122589C2 (uk) 2020-12-10
RU2727179C2 (ru) 2020-07-21
JP2018536703A (ja) 2018-12-13
AU2016348493B2 (en) 2021-02-25
MX2018005121A (es) 2018-06-06
US10710985B2 (en) 2020-07-14
LT3371168T (lt) 2020-10-12
AR106588A1 (es) 2018-01-31
MY197370A (en) 2023-06-14
CN108349944B (zh) 2021-03-30
IL258656A (en) 2018-06-28
PL3371168T3 (pl) 2020-11-02
PE20181885A1 (es) 2018-12-07
SG11201803796SA (en) 2018-06-28
TW201726654A (zh) 2017-08-01

Similar Documents

Publication Publication Date Title
MA43159B1 (fr) Dérivés d'indoline-2-one
EA033420B1 (ru) Производные индолин-2-она или пирролопиридин-2-она, обладающие антипсихотической активностью
MX2019010577A (es) Derivados de benzodiazepina, composiciones, y metodos para tratar el deterioro cognitivo.
MA34828B1 (fr) Procédés et produits médicamenteux destinés au traitement de la maladie d'alzheimer
MX2019007338A (es) Derivados de benzodiazepina, composiciones y métodos para tratar deterioro cognitivo.
EA201890090A1 (ru) Производные бензодиазепина, композиции и способы для лечения когнитивного нарушения
MA33659B1 (fr) Dihydrobenzocycloalkyl-oxyméthyl-oxazolopyrimidinones substituées, préparation et utilisation de celles-ci
MA46611B1 (fr) Traitements combinés comprenant des imidazopyrazinones pour le traitement de troubles psychiatriques et/ou cognitifs
MA42397B1 (fr) 4-azaindoles substituées et leur utilisation comme modulatoeurs de la récepteur glun2b
MA43113B1 (fr) Anticorps anti-htr a1 et méthodes d'utilisation de ceux-ci
PH12016501863A1 (en) Heteroaromatic compounds and their use as dopamine d1 ligands
EA201390710A1 (ru) Производные бензодиазепина, композиции и способы для лечения когнитивного нарушения
EA201290764A1 (ru) Способы и композиции для улучшения когнитивной функции
PH12016501993A1 (en) Heteroaromatic compounds and their use as dopamine d1 ligands
MX2020009810A (es) Nuevo uso de las composiciones microbiológicas.
AR106591A1 (es) Derivados de indolin-2-ona
EA201892461A1 (ru) Продукт бензодиазепина с активностью на центральную нервную и сердечно-сосудистую системы
TH1801002657A (th) อนุพันธ์อินโดลิน-2-โอน
LU100823B1 (en) Method of performing differential diagnosis of neurodegenerative diseases in a subject
BR112016024149A2 (pt) derivados de indolin-2-ona e 1,3-di-hidro-pirrol[3,2-c]piridin-2-ona
CERQ INC 2016, Zarqa University, Jordan April 6, 2016
EA201691290A1 (ru) Бензодиазепиновые производные, композиции и способы для лечения когнитивного нарушения
Maffei GABAergic inhibition in visual cortical plasticity
EA201992055A1 (ru) Ингибиторы бета-секретазы
Sekita-Krzak et al. ETIOPATHOGENETICAL AND CLINICAL RELATION OF STRESS AND DEPRESSION